News & Events

September 28, 2022
Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Suzanne Zoumaras as Executive Vice President, Head of Human Resources. Ms. Zoumaras is an experienced human capital leader who brings over two decades of experience in developing talent and growth strategies for a wide range of life sciences and technology companies, from private stage start-ups to large, publicly traded commercial organizations.
August 23, 2022
Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Daniel Sipes as Senior Vice President, Head of Technology. Mr. Sipes brings over two decades of experience in developing and implementing new technologies for drug discovery to Plexium, with a focus on next-generation high throughput screening and novel assay development.
July 12, 2022
Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Brian Wong as a member of its Board of Directors. Dr. Wong is a well-respected leader with more than two decades of experience in the biotechnology and large pharmaceutical sectors, including a track record of advancing more than 20 programs from discovery to late-stage clinical development and including through approval.
May 2, 2022
Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Stephen Mullennix as Chief Financial Officer (CFO). Mr. Mullennix brings more than 20 years of financial and operational expertise in the biotechnology and private equity sectors to Plexium, with a strong background in developing and executing corporate and financial growth strategies.
April 27, 2022
Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) have entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions. This collaboration combines AbbVie’s extensive neuroscience capabilities with Plexium’s comprehensive TPD platform that enables the discovery of novel therapies toward historically challenging drug targets.
April 6, 2022
Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced that Plexium President & CEO, Percival Barretto-Ko, will participate at the Longwood Healthcare Leaders Spring MIT webconference in a panel titled Cultivating An Ecosystem Of Partners on Wednesday, May 4, 2022. The conference is being held virtually May 4-5, 2022.
February 22, 2022
Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the completion of an oversubscribed $102M financing, led by BVF Partners, L.P. and TCG X, with participation from new investors Softbank Vision Fund 2, RA Capital Management, Surveyor Capital (a Citadel company), and Pappas Capital. Existing investors The Column Group, DCVC Bio, Pivotal bioVenture Partners, Lux Capital, M Ventures, CRV and Neotribe Ventures also participated in the round.
February 2, 2022
Collaboration Combines Plexium’s Novel Technology Platform With Amgen’s Early Discovery Expertise to Identify and Develop new Therapeutic Agents in Cancer and Other Serious Diseases THOUSAND OAKS and San Diego, Calif. (Feb. 03, 2022) – Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted […]
November 3, 2021
San Diego, Calif., November 4, 2021 – Plexium Inc., (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of experienced biopharmaceutical leader Percival Barretto-Ko as President and Chief Executive Officer and a member of the Board of Directors. Mr. Barretto-Ko joins Plexium following a sixteen-year tenure with Astellas Pharma Inc., a […]
October 7, 2021
SAN DIEGO, Oct. 5, 2021 – Plexium Inc., (Plexium), a biotech company focused on discovering and developing protein degrading therapeutics directed towards historically challenging drug targets, today announced that company management will present and host one-on-one meetings at the Solebury Trout/BMO Fall Private Company Showcase 2021. The company will present on Thursday, October 14th, 2021 at […]